• 1. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099

1-Methyl-1H-benzodimidazol-7-amine (CAS No. 21577-25-3): A Comprehensive Overview

1-Methyl-1H-benzodimidazol-7-amine (CAS No. 21577-25-3) is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential biological activities. This compound, also known as 1-methylbenzimidazol-7-amine, belongs to the class of benzimidazoles, which are widely studied for their diverse biological effects, including antifungal, antiviral, and anticancer activities.

The chemical structure of 1-Methyl-1H-benzodimidazol-7-amine consists of a benzimidazole ring with a methyl group and an amino group attached at specific positions. The benzimidazole core is a privileged scaffold in medicinal chemistry, known for its ability to interact with various biological targets. The presence of the methyl and amino groups further enhances its pharmacological profile by modulating its physicochemical properties and biological activity.

Recent studies have highlighted the potential of 1-Methyl-1H-benzodimidazol-7-amine in various therapeutic areas. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent antifungal activity against several clinically relevant fungal pathogens, including Candida albicans and Aspergillus fumigatus. The mechanism of action involves the disruption of fungal cell wall integrity, making it a promising candidate for the development of new antifungal agents.

In addition to its antifungal properties, 1-Methyl-1H-benzodimidazol-7-amine has shown potential as an anticancer agent. Research conducted at the National Cancer Institute revealed that this compound can selectively inhibit the growth of human cancer cell lines, particularly those derived from breast and lung cancers. The anticancer activity is attributed to its ability to induce apoptosis and cell cycle arrest, which are critical processes in cancer cell death.

The pharmacokinetic properties of 1-Methyl-1H-benzodimidazol-7-amine have also been extensively studied. Preclinical data indicate that this compound has favorable oral bioavailability and a reasonable half-life, making it suitable for further development as an oral therapeutic agent. Moreover, its low toxicity profile in animal models suggests that it may have a favorable safety margin when used in clinical settings.

In terms of synthetic methods, several efficient routes have been developed for the preparation of 1-Methyl-1H-benzodimidazol-7-amine. One notable approach involves the condensation of 2-aminothiophenol with formamide followed by methylation with methyl iodide. This method yields high purity product with good yields, making it suitable for large-scale production.

The potential applications of 1-Methyl-1H-benzodimidazol-7-amine extend beyond its direct therapeutic uses. It serves as a valuable building block in the synthesis of more complex molecules with enhanced biological activities. For example, researchers at the University of California have utilized this compound as a key intermediate in the development of novel HIV protease inhibitors, which are crucial for managing HIV infection.

In conclusion, 1-Methyl-1H-benzodimidazol-7-amine (CAS No. 21577-25-3) is a multifaceted compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique structural features and diverse biological activities make it an attractive candidate for further investigation and development into novel therapeutic agents. Ongoing research continues to uncover new applications and mechanisms of action, solidifying its position as an important molecule in the field.

• 26530-93-8(1-methyl-1H-benzimidazol-6-amine Dihydrochloride)
• 34594-71-3(1H-Benzimidazol-5-amine,N,N,1-trimethyl-)
• 34594-86-0(1H-Benzimidazol-5-amine,N,1-dimethyl-)
• 155242-98-1(1-Methyl-1H-benzodimidazol-4-amine)
• 16242-47-0(1H-Benzimidazole-1-ethanol,7-amino-)
• 10394-38-4(1-methyl-1H-1,3-benzodiazol-5-amine)
• 103755-54-0(Formamide,N-(1-methyl-1H-benzimidazol-7-yl)-)
• 21577-26-4(1H-Benzimidazol-7-amine,1,2-dimethyl-)
• 16242-48-1(1H-Benzimidazol-7-amine,1-(2-chloroethyl)-)
• 102872-47-9(1H-Benzimidazole-1-ethanol,4-amino-)